Patient Power
Research presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting examined Bruton tyrosine kinase BTK inhibitors, a standard therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and the potential side effects of this treatment related to the cardiovascular system. BTK inhibitors have shown success in treating CLL because they block proteins that help this cancer grow. Dipenkumar Modi, M.D., hematologist and medical oncologist, and member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos, gives some advice before patients begin therapy with BTK inhibitors.
Read the article here.